China FDA changes will speed up approval process, says CRO

By Flora Southey

- Last updated on GMT

Four new draft policies were released May 11. (Image: iStock/Golden_Brown)
Four new draft policies were released May 11. (Image: iStock/Golden_Brown)
Proposed changes to drug, medical device and clinical testing regulations provide stimulus for conducting trials in China, says CRO George Clinical.

The contract research organisation’s (CRO) managing director, Philip Gregory, said the China Food and Drug Administration’s (CFDA) four new draft policies​ (in Chinese), released May 11, herald an exciting new era for drug and device development.

“If implemented in full, these proposed changes will standardise regulatory requirements, allow for greater use of foreign data broadening eligibility of sites to conduct trials, provide greater transparency of the ethics processes, and ultimately shorten approval timelines,” ​he said.

According to the China-based director, the policies support investigators and clinical testing organisations to carry out clinical trials, improve the clinical trial review process, accept overseas clinical trial data, and support exploratory clinical research, which, if approved, will make the CFDA regulations comparable with other major global players.

The proposed changes show a “proactive response by a regulatory body keen to improve the overall drug development process and make new medicines available faster for the Chinese population,” ​he said.

The draft policies – open for public comment until June 10 – highlight Chinese regulators’ continued commitment to improving access to medicines.

The CFDA released proposed changes​ to drug trial and API importation laws on March 17 to shorten clinical trials and approval times to meet “public demand for new drugs.” 

Related news

Show more

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers